Skip to main content
SpringerLink
Log in

Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

References

  1. Logue JM, Chavez JC (2021) How to sequence therapies in diffuse large B-cell lymphoma post-CAR-T cell failure. Curr Treat Options Oncol 22(12):112. https://doi.org/10.1007/s11864-021-00906-4

    Article  PubMed  Google Scholar 

  2. Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S, Li Y (2019) Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol 10:2664. https://doi.org/10.3389/fimmu.2019.02664

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F, Gros FX, Choquet S, Bories P, Feugier P, Casasnovas O, Bay JO, Mohty M, Joris M, Gastinne T, Sesques P, Tudesq JJ, Vercellino L, Morschhauser F, Gat E, Broussais F, Houot R, Thieblemont C (2022) Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood 140(24):2584–2593. https://doi.org/10.1182/blood.2022016945

    Article  CAS  PubMed  Google Scholar 

  4. Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose JM, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill BT, Miklos DB (2021) Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 137(13):1832–1835. https://doi.org/10.1182/blood.2020006245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR (2023) Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma. J Clin Oncol 41(4):745–755. https://doi.org/10.1200/JCO.22.00597

    Article  CAS  PubMed  Google Scholar 

  6. Westin J (2019) Ibrutinib and lenalidomide: when 1+1 = >2. Blood 134(13):996–998. https://doi.org/10.1182/blood.2019002237

    Article  CAS  PubMed  Google Scholar 

  7. Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, Knapp M, Delioukina M, Kingsley E, Ping J, Beaupre DM, Neuenburg JK, Ruan J (2019) Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood 134(13):1024–1036. https://doi.org/10.1182/blood.2018891598

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna KM, Johnson R, Verhoef G, Cunningham D, de Vos S, Kassam S, Fayad L, Radford J, Bailly S, Offner F, Morgan D, Munoz J, Ping J, Szafer-Glusman E, Eckert K, Neuenburg JK, Goy A (2023) The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study. EClinicalMedicine 56:101779. https://doi.org/10.1016/j.eclinm.2022.101779

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the patient for allowing us to report his case and acknowledged the support of nurses and laboratory scientists who had participated in the process of diagnosis and treatment.

Funding

This work was supported by a grant from the National Natural Science Foundation of China (No. 82072927).

Author information

Authors and Affiliations

  1. Biotherapy Center, Affiliated Qingdao Central Hospital of Qingdao University, 127 Siliunan Road, Qingdao, 266042, China

    Changyou Li, Danni Zhu & Peng Zhao

  2. Department of Hematology, Affiliated Qingdao Central Hospital of Qingdao University, 127 Siliunan Road, Qingdao, 266042, China

    Xiyuan Zhang & Ling Wang

  3. The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, China

    Xiaocui Bu

Authors
  1. Changyou Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiyuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Danni Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaocui Bu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ling Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CL, XZ, DZ, and XB collected, verified, and interpreted patient information and drafted the manuscript. PZ and LW designed the research and critically reviewed and revised the final draft. All authors approved the submitted version of the paper.

Corresponding authors

Correspondence to Ling Wang or Peng Zhao.

Ethics declarations

Ethics approval

Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 14 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, C., Zhang, X., Zhu, D. et al. Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report. Ann Hematol 102, 3625–3627 (2023). https://doi.org/10.1007/s00277-023-05421-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05421-0

Search

Navigation